CLINICAL TRIALS PROFILE FOR SODIUM ZIRCONIUM CYCLOSILICATE
✉ Email this page to a colleague
All Clinical Trials for sodium zirconium cyclosilicate
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02088073 ↗ | Safety & Efficacy of Zirconium Silicate Dosed for 28 Days in Hyperkalemia. | Completed | ZS Pharma, Inc. | Phase 3 | 2014-03-31 | It is hypothesized that ZS is more effective than placebo control (alternative hypothesis) in maintaining mean double-blind randomized maintenance phase (DBRMP) Day 8-29 serum potassium levels (3.5 - 5.0 mmol/l, inclusive) among hyperkalemic subjects in whom normokalemia was established during the open-label acute phase versus no difference between each ZS dose (highest to lowest) versus placebo control (null hypothesis). |
| NCT02107092 ↗ | Open-label Safety & Efficacy of ZS (Sodium Zirconium Cyclosilicate)10g qd to Extend Study ZS-004 in Hyperkalemia. | Completed | ZS Pharma, Inc. | Phase 3 | 2014-05-31 | Subjects who completed the Double-blind Randomized Maintenance Phase (DBRMP) Study Day 29 visit in ZS-004 (NCT 02088073) and have an i-STAT potassium value that is 3.5 to 6.2 mmol/l inclusive or who discontinued during ZS-004 due to hypo- or hyperkalemia in the DBRMP and have a mean i-STAT potassium value from two consecutive measurements at 0 and 60 minutes on Acute Phase Day 1/Maintenance Phase Day 1 that is 3.5 to 6.2 mmol/l inclusive may have the option to participate in ZS-004E (NCT 021070920). Subjects who discontinued from study ZS-004 due to any other reasons (e.g. adverse events, poor compliance, investigator decision) will not be entered into study ZS-004E. All subjects who continue into the extension study must begin dosing within two (2) days after the last dose of investigational product in ZS-004. |
| NCT02163499 ↗ | Open-label Safety and Efficacy of Sodium Zirconium Cyclosilicate for up to 12 Months | Completed | ZS Pharma, Inc. | Phase 3 | 2014-06-30 | The Open-Label Maintenance Study contains an Acute Phase, in which subjects will be dosed with ZS 10 g three times daily (tid) for 24 to 72 hours, followed by a long-term Maintenance Phase. |
| NCT03127644 ↗ | ZS Ph2/3 Dose-response Study in Japan | Completed | AstraZeneca | Phase 2/Phase 3 | 2017-06-14 | To assess efficacy of 5 g three times daily (TID) and 10 g TID ZS versus placebo in Japanese patients with hyperkalemia (serum potassium [S-K] ≥ 5.1 mmol/L and ≤ 6.5 mmol/L). |
| NCT03172702 ↗ | Open-label Safety of Sodium Zirconium Cyclosilicate for up to 12 Months in Japanese Subjects With Hyperkalemia | Completed | AstraZeneca | Phase 3 | 2017-09-04 | The Open-Label Maintenance Study contains an Correction Phase, in which subjects will be dosed with ZS 10 g three times daily (tid) for 24 to 72 hours, followed by a 12-month long-term Maintenance Phase. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for sodium zirconium cyclosilicate
Condition Name
Clinical Trial Locations for sodium zirconium cyclosilicate
Trials by Country
Clinical Trial Progress for sodium zirconium cyclosilicate
Clinical Trial Phase
Clinical Trial Sponsors for sodium zirconium cyclosilicate
Sponsor Name
